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Colorectal cancer (CRC) is one of the most common malignancies worldwide. Early
stage CRC patients have a good prognosis. If distant metastasis occurs, the 5-year
survival drops below 10%. Despite treatment success over the last decades, treatment
options for metastatic disease are still limited. Therefore, novel targets are needed to
foster therapy of advanced stage CRC patients and hinder progression of early stage
patients into metastasis. A novel target is the crucial oncogene Metastasis-Associated
in Colon Cancer 1 (MACC1) involved in molecular pathogenesis of CRC metastasis.
MACC1 induces cell proliferation and motility, supports cellular survival and rewires
metabolism resulting in increased metastasis in vivo. MACC1 is a prognostic biomarker
not only for CRC but for more than 20 solid cancer entities. Inflammation plays a pivotal
role in tumorigenesis, tumor progression and metastasis. For CRC, inflammatory bowel
disease and ulcerative colitis are important inflammation associated risk factors. Certain
cytokines, such as TNF-α and IFN-γ, are key factors in determining the contribution of
the inflammatory process to CRC. Knowledge of the connection between inflammation
and MACC1 driven tumors remains unclear. Gene expression analysis of CRC cells
after cytokine stimulation was analyzed by qRT-PCR and Western blot. Cellular motility
was assessed by Boyden chamber assays. MACC1 promoter activity after stimulation
with pro-inflammatory cytokines was measured using promoter-luciferase constructs.
To investigate signal transduction from receptor to effector molecules, blocking
experiments using neutralizing antibodies and knockdown experiments were performed.
Following TNF-α stimulation, MACC1 and c-Jun expression were significantly increased
at the mRNA and protein level. Knockdown of c-Jun reduced MACC1 inducibility
following TNF-α stimulation. TNF-α promoted MACC1-induced cell migration that was
reverted following MACC1 knockdown. Moreover, MACC1 and c-Jun expression were
downregulated by blocking TNFR1, but not TNFR2. Knock down of the NF-κB subunit,
p65, reduced basal MACC1 and c-Jun mRNA expression levels. Adalimumab, a clinically
approved monoclonal anti-TNF-α antibody, hindered MACC1 induction. The present
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study highlights that TNF-α regulates the induction of MACC1 via the NF-κB subunit
p65 and the transcription factor c-Jun in CRC cells. This finding unravels a novel
signaling pathway upstream of MACC1 and provides a potential therapeutic target for
the treatment of CRC patients with an associated inflammation.
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INTRODUCTION
Inflammation is a defense mechanism of the immune system
of higher multicellular organisms (1). It is triggered by stimuli
including pathogens, injuries, chemicals or radiation (2). The
protective responses are essentially connected to the healing
process after the trigger is removed (3). Inflammation is
mediated and controlled by different cell types and secreted
proteins including pro-inflammatory cytokines (4). The major
pro-inflammatory cytokines in different diseases are TNF-
α and IFN-γ (5–7). Both belong to the group of immune
modulating molecules that act through specific cell-surface
receptors and participate in autocrine, paracrine and endocrine
signaling (8–11). Theymodulate the innate and adaptive immune
system (4, 12). More importantly, they are also associated with
chronic inflammation and represent crucial factors in tumor
development (13–15). Chronic inflammation is known as causal
risk factor for tumor development, but the intimate connection
of inflammation and tumor development at the molecular level is
still only partly understood.
Colorectal cancer (CRC) is a major cause of morbidity and
mortality worldwide and especially in developed contries (16, 17).
It contributes to more than 8% of all cancer incidences that affect
both men and women, making it the third most common cancer
globally (18). There are numerous risk factors for CRC like diet,
“Western lifestyle,” excessive alcohol and tobacco intake and,
environmental exposure (19–22). Diseases like ulcerative colitis
and Crohn’s disease connect the formation of sporadic CRC
and chronic inflammatory conditions (23–25). Sporadic CRC
accounts for the majority of all CRC cases. A smaller fraction of
about 10–15% of all CRC cases is based on hereditary risk factors
like in familial adenomatous polyposis (FAP) and hereditary
nonpolyposis colorectal cancer (HNPCC) (26, 27). There is
growing evidence that inflammation is not only connected to
sporadic cases of CRC but that reduced inflammatory responses
can equally reduce or delay the formation of hereditary CRCs
(27, 28). Ulcerative colitis is responsible for 1% of all CRC
cases due to chronic inflammation affecting the mucosa of the
colon and rectum, and Crohn’s disease and here in particular
Crohn’s colitis has also been shown to slightly increase the risk
(16). Inflammation is causing differential gene expression for a
broad spectrum of genes. Therefore, it is needed to understand,
which of these genes are the most important drivers of CRC and
might serve as biomarkers and as therapeutic targets in patient
tailored treatments.
One such driver of tumor progression is the gene Metastasis-
Associated in Colon Cancer 1 (MACC1). The importance of
MACC1 has been first demonstrated in CRC as prognostic
marker of metastasis formation and metastasis-free survival
(29). Both MACC1 mRNA and protein are highly expressed in
CRC tissues with metachronous metastases compared to tumors
without metastases and to normal tissue. The expression of
MACC1 is increased during the transition from adenomas to
carcinomas (30, 31). This suggests that MACC1 represents an
independent early prognosticmarker for CRCmetastasis (32, 33).
Besides CRC, MACC1 is meanwhile also a prognostic marker for
more than 20 solid tumor entities (34).
MACC1 is a causal driver of tumor progression and
metastasis. The reason for the increasedMACC1 gene expression
is largely unknown. Here we analyzed the connection of
inflammation and MACC1 expression in the context of pro-
inflammatory cytokines.
MATERIALS AND METHODS
Immunhistochemical Staining of MACC1 in
Patient Paraffin Tissue Sections
Written informed consent was obtained from all patients.
All experiments were approved by the institutional review
board of the Charité–Universitätsmedizin Berlin and conducted
accordingly. The authors complied with all relevant ethical
regulations for research involving human participants. MACC1
protein expression was assessed in 14 tissue samples (five male,
nine female patients, median age 55.5 years) of ulcerative colitis
and Crohn’s disease patients.
For paraffin removal and antigen retrieval tissues were treated
with Xylol, 2:1 vol/vol aceton/Tris and finally boiled in 10mM
citrate buffer pH 6.3. Specimens were blocked for 30min
at room temperature with horse serum and incubated with
primary MACC1 antibody for 2 h (HPA020103, Sigma Aldrich,
Munich, Germany). After washing, the slides were incubated
with a biotinylated secondary anti rabbit antibody (30min, room
temperature) and streptavidin-peroxidase (VECTASTAIN Elite
ABC HRP Kit, PK-6101 Vector Laboratories, Burlingame, CA,
USA) for another 30min at room temperature. Finally, staining
was visualized with 3,3′-diaminobenzidin (DAB Peroxidase
(HRP) Substrate Kit, SK-4100, Vector Laboratories) and nuclei
were stained with haemalaun. The tissues were photographed
using a magnification of 100 x for the overviews and 400 x for
the insets.
Cell Culture
HCT116 (LGC Standards, Wesel, Germany) human CRC
cells were cultured at 37◦C, 100% atmospheric humidity
and 5% CO2 in RPMI (Thermo Fisher Scientific, Waltham,
MA, USA) –emented with 10% fetal calf serum (Bio&Sell,
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Feucht, Germany). Cells were harvested using trypsin/EDTA
(Thermo Fisher Scientific) and counted in an automated
cell counter (NanoEnTek, Seoul, Korea). Cells were regularly
verified as mycoplasma-negative (Lonza, Basel, Switzerland).
Authentication of cell lines was performed by short tandem
repeat (STR) genotyping (Multiplexion, Heidelberg, Germany).
STR genotypes were consistent with published genotypes.
Cytokine Treatment
Recombinant human TNF-α and IFN-γ (Peprotech, Hamburg,
Germany) were stored at −20◦C following reconstitution to 0.1
mg/ml in sterile, deionized water. To maintain the stability of
the cytokines, small aliquots were created for single use. Briefly,
1 × 106 cells/well were seeded in 6-well plates and allowed to
adhere for 24 h. Subsequently, cells were treated with increasing
concentrations (1, 10, 100 ng/ml) of cytokines and harvested after
24 and 48 h. Each experiment was performed in triplicate.
siRNA Transfection
Preestablished siRNAs targeting c-Jun (Thermo Fisher
Scientific), p65 (kind gift of Prof. Claus Scheidereit, Max-
Delbrück-Center for Molecular Medicine, Berlin, Germany), as
well as scrambled siRNA (Thermo Fisher Scientific) serving as a
negative control, were used. 3 × 105 HCT116 cells were seeded
in 6-well plates and cultured for 24 h. siRNAs were transfected
using the RNAiMAX RNAiMAX transfection reagent following
manufacturer’s recommendations. Cells were harvested after
incubation for 24 and 48 h. Experiments were performed in three
biological replicates.
Plasmid Transfection
To analyze MACC1 promoter activity, pGL4.17-based (Promega,
Fitchburg, WI, USA) promoter reporter constructs generated
earlier were transfected prior to TNF-α treatment into HCT116
cells (35). Prior transfection using TransIT 2020 (Mirus,
Madison, WI, USA) following manufacturer’s recommendations,
7.5 × 104 cells were seeded into 24-well plates and allowed
to adhere for 24 h. To normalize for transfection efficiency,
the pGL4.74 (Promega) encoding for renilla luciferase
plasmid was transfected in parallel. Following addition of
the transfection complex the cells were grown for 24 h before
TNF-α treatment started.
Dual Luciferase Reporter Gene Assay
The activities of the firefly and renilla luciferases were measured
using the Dual-Luciferase reporter assay system (Promega). Cells
transiently expressing the luciferase constructs were lysed in
passive lysis buffer with gentle shaking for 15min at room
temperature. Equal amounts of lysate and luciferase substrate
were added to 96-well luminescence plates (Corning, Corning,
NY, USA). The firefly luminescence was quantified first using
an Infinite M200 pro 96-well plate reader (Tecan, Männedorf,
Switzerland). Following addition of the Stop&Glo reagent, the
renilla luciferase luminescence was assessed. Firefly luciferase
activities were normalized to renilla luciferase readings.
Cell Migration
For the evaluation of cell migration, the Boyden chamber assay
was used. Membrane inserts (Sigma) with a pore size of 8µm
were used in 24-well plates. Cells were serum-starved overnight.
The following day, 600 µl medium containing 10% FCS, without
or with increasing amounts TNF-α (1, 10, 100 ng/ml), were added
to each lower chamber. Then, 3 × 105 cells in 300 µl medium
containing 1% FCS, without or with increasing amounts of TNF-
α (1, 10, 100 ng/ml), were seeded into each transwell upper
chamber. Cells were incubated for 24 h to allow migration. The
cells that had migrated to the lower side of the membrane were
harvested with trypsin/EDTA and pooled with the cells in the
lower chamber prior to centrifugation (200x g, 5min at room
temperature). To analyze relative cell numbers the cell titer-glo
reagent (Promega) was used. After incubation for 10min in the
dark, luminescence intensity wasmeasured with an InfiniteM200
pro 96-well plate reader. Each migration assay was performed
three times in triplicate.
TNF-α and Adalimumab or TNFR Antibody
Treatment
Adalimumab (HUMIRA R©, Il, USA, 100 mg/ml) was stored at
4◦C. For TNF-α treatment of HCT116 cells, 2 × 105 cells were
plated in 6-well plates and allowed to adhere for 24 h. Then, TNF-
α was diluted in RPMI media and added to fresh cell media.
Sterile water served as control treatment. For co-treatment, TNF-
α and Adalimumab were added to fresh RPMI 10% FBS media
to achieve a final concentration of 10 ng/ml TNF-α and 1, 10, or
100µg/ml Adalimumab. The cells were then incubated for 24 h
at 37◦C with 5% CO2 before harvesting for RNA and protein
isolation. For experiments blocking TNFR1 or TNFR2, cells were
pretreated with the respective antibodies (TNFR1: MAB225-100
R&D; TNFR2:MAB726-100, R&D Systems,MN, USA) 1 h before
adding 10 ng/ml TNF-α.
Total RNA Isolation, cDNA Synthesis and
Quantitative Real-Time PCR
The total RNAwas isolated using the GeneMatrix Universal RNA
Purification Kit (Roboklon, Berlin, Germany), according to the
manufacturer’s instructions. Briefly, cells were harvested, lysed
and applied to the columns. After washing the columns RNA
was eluted with 50µl nuclease-free H2O. RNA concentration was
quantified using a NanoDrop spectrophotometer (Thermo Fisher
Scientific). The samples were stored at−80◦C until further use.
For reverse transcription 50 ng total RNA was used. Reverse
transcription was performed with 2.5µM random hexamers in
5mM MgCl2, 1x PCR buffer, 4mM dNTPs pool, 1 U/µl RNAse
inhibitor and 2.5 U/µl MuLV reverse transcriptase (all Thermo
Fisher Scientific). The reaction was carried out at 42◦C for
45min, 99◦C for 5min and 5◦C for 5min. cDNA was stored at
−20◦C until use.
Quantitative PCR was performed using SYBR Green dye
chemistry (GoTaq qPCR Master Mix, Promega) in a LightCycler
480 II system (Hoffmann—La Roche, Basel, Switzerland). The
data were evaluated by the LightCycler 480 Software release 1.5.0
SP3. All primer sequences are summarized in Table 1.
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TABLE 1 | Primer used for qRT-PCR.
Gene Sequence
MACC1F 5′− TTCTTTTGATTCCTCCGGTGA−3′
MACC1 R 5′− ACTCTGATGGGCATGTG TG−3′
c-Jun F 5′− CAGGTGGCACAGCTTAAACA−3′
c-Jun R 5′− GTTTGCAACTGCTGCGTTAG−3′
Sp1F 5′− GCTCTGAACATCCAGCAAAA−3′
Sp1 R 5′− CAGAGTTTGGAACAGCCTGA−3′
p65 F 5′− ACAACCCCTTCCAAGTTCCT−3′
p65 R 5′− ATCTTGAGCTCGGCAGTGTT−3′
GAPDH F 5′− GAAGATGGTGATGGGATTTC−3′
GAPDH R 5′− GAAGGTGAAGGTCGGAGT−3′
G6PDH F 5′− ATCGACCACTACCTGGGCAA−3′
G6PDH R 5′− TTCTGCATCACGTCCCGGA−3′
F, forward; R, reverse.
Protein Extraction and Western Blotting
For total protein extraction, harvested and washed cells were
lysed in RIPA buffer supplemented with cOmplete Protease
Inhibitor Cocktail (Sigma) for 15min on ice. Supernatants were
collected following centrifugation at 20,000x g for 20min at 4◦C
and stored at−80◦C until further use.
The protein concentration of the supernatant was determined
by a bicinchoninic acid (BCA) protein assay (Thermo Fisher
Scientific) according to the manufacturer’s instructions. The
lysates were diluted in PBS, and quantified relative to a BSA
standard curve. The absorbance was measured at 560 nm using
the Tecan Infinite M200 pro.
For Western blotting, 20 µg total protein was mixed
with 1x NUPAGE sample buffer (Thermo Fisher Scientific),
supplemented with 10% DTT, and heated for 10min at 95◦C.
Proteins were separated on 10% NuPAGE Bis-Tris gels (Thermo
Fisher Scientific) in 500ml MOPS buffer (Carl Roth, Karlsruhe,
Germany) at 150V for 1 h. The proteins were then transferred
to a nitrocellulose membrane using a semi-dry turbo-blot
(Bio-Rad, Hercules, CA, USA) electrotransfer apparatus. After
blocking the membrane in 5% skimmed milk powder (Carl
Roth) in TBST for 1 h at room temperature, the membrane
was incubated with primary antibodies at 4◦C overnight (rabbit
anti-MACC1, HPA020081, Sigma; rabbit anti-c-Jun, 60A8, Cell
Signaling; mouse anti-β-actin, A1978, Sigma). Protein bands
were visualized with a suitable horseradish peroxidase conjugated
secondary antibodies (anti-rabbit IgG-HRP, W4011, Promega;
anti-mouse IgG-HRP, 31430, Thermo) and WesternBright
ECL (Biozym, Hessisch Oldendorf, Germany) substrate. Light
emission was documented using Fuji medical X-Ray films (Kisker
Biotech, Schweinfurt, Germany).
Statistical Analysis
Statistical analysis was performed using GraphPad PrismVersion
6 (GraphPad Software, San Diego, CA, USA). Comparisons of
controls with multiple experimental groups were carried out
using one-way analysis of variance (ANOVA) followed by a
Dunnett post-hoc test. Statistical significance was defined for p-
values below 0.05, with ∗p ≤ 0.05, ∗p ≤ 0.01 and ∗∗∗p ≤ 0.001
and ∗∗∗∗p ≤ 0.0001.
RESULTS
MACC1 Protein Level Is Increased in
Inflamed Patient Tissue
We and other groups have shown that MACC1 expression levels
are increased especially in tumor tissue of patients with poor
outcome (34). For CRC it was shown that MACC1 occurs
very early during the transition from adenoma to carcinoma.
In order to provide insights of MACC1 gene expression in
inflamed tissue before tumor development we stained tissues
from ulcerative colitis and Crohn’s disease patients for MACC1.
A pathologist confirmed active inflammation and evaluated the
microphotographs. Specimens of non-inflamed tissue showed
weak MACC1 expression only (Figure 1). By contrast, inflamed
tissues from ulcerative colitis and Crohn’s disease patients
revealed moderate to strong MACC1 expression mainly in the
cytoplasm of the cells (Figure 1), indicating the association
of chronic inflammation and increase in MACC1 expression.
Tissues outside of inflamed areas of ulcerative colitis and Crohn’s
disease patients served as controls.
TNF-α and IFN-γ Regulate MACC1 mRNA
and Protein Expression Levels
To evaluate the effect of inflammation on MACC1 in epithelial
CRC cells, we assessed the impact of twomajor pro-inflammatory
cytokines, TNF-α and IFN-γ on MACC1 expression. The CRC
cell line HCT116 was treated with increasing concentrations of
either TNF-α (Figure 2A) or IFN-γ (Figure 2B) for 24 and 48 h,
respectively. ThemRNA and protein expression levels ofMACC1
were determined by qRT-PCR and Western blot.
Compared with the untreated control cells, MACC1 mRNA
expression levels were significantly increased by 3-fold upon
treatment with 1 ng/ml (p < 0.05), 10 ng/ml (p < 0.01), and
100 ng/ml (p < 0.01) TNF-α (Figure 2A, left panel). Following
48 h of treatment, the increase in mRNA expression levels of
MACC1 declined but was still significantly elevated by 1.5- to
2-fold. Consistent with the increase in mRNA expression levels,
MACC1 protein expression was also upregulated following 24
and 48 h TNF-α treatment in a dose-dependent manner. This
finding was confirmed in three different established cell lines and
three different primary cell models (Supplementary Figure 1).
Similarly, HCT116 cells were exposed to increasing
concentrations of IFN-γ for 24 and 48 h (Figure 2B). MACC1
mRNA and protein expression levels were determined by
qRT-PCR and Western blotting, respectively. For this cytokine,
the increase in the MACC1 mRNA levels was still there but
not as pronounced as for TN-α treatment. These experiments
demonstrate that stimulation with pro-inflammatory cytokines
was able to upregulate MACC1 mRNA and protein expression in
a dose- and time-dependent manner.
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FIGURE 1 | MACC1 protein expression is increased in inflamed tissue. MACC1 protein expression was assessed in 14 tissue samples (five male, nine female
patients, median age 55.5 years) of ulcerative colitis and Crohn’s disease patients. Besides typical signs of extensive inflammation, areas of actively inflamed tissue
show moderate to strong MACC1 staining especially in epithelial tissue compared to adjacent healthy tissue. The tissues were photographed using a magnification of
100 x for the overviews and 400 x for the insets.
TNF-α and IFN-γ Induce Cell Migration
As shown above, exposure to TNF-α induces MACC1. To
explore, if this increased MACC1 expression results in increased
migratory potential of cells, we tested HCT116 cells in the
Boyden chamber assay. First, we confirmed MACC1-dependent
changes in migration by either overexpressing MACC1 by stable
transfection or specific downregulation of MACC1 by siRNA.
Cell migration was increased with elevated MACC1 expression
and decreased if MACC1 was knocked down by siRNA
(Figures 3A,B). Treatment with increasing concentrations of
TNF-α (1, 10, or 100 ng/ml) was performed for 24 h. TNF-α
induced cell migration by more than 2-fold at a concentration
of 1 ng/ml (Figure 3A), compared with unstimulated cells.
Upon treatment with 10 ng/ml TNF-α, cell migration was even
stronger induced by 3-fold in HCT116 cells, compared with
control cells. Interestingly, at a concentration of 100 ng/ml
TNF-α, cell migration was not as strongly induced as at
lower TNF-α concentrations but still elevated above control
levels. To confirm this we tested in addition to the Boyden
chamber migration assay cellular motility in the wound healing
(scratch) assay. TNF-α induced faster wound closure compared
to control cells (Supplementary Figure 2A). The data clearly
indicates that TNF-α was able to induce cell migration in vitro
in a dose-dependent manner. To determine the role of the
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FIGURE 2 | Effects of TNF-α and IFN-γ stimulation on the MACC1 gene expression. HCT116 cells were treated with increasing concentrations of TNF-α (1, 10,
100 ng/ml) (A) and IFN-γ (1, 10, 100 ng/ml) (B) for 24 h (left side) and 48 h (right side). Cells without cytokine treatment served as controls. MACC1 mRNA expression
levels were determined by qRT-PCR and normalized to GAPDH. Evaluation of MACC1 protein expression levels was performed by Western blot, and β-actin served
as loading control. Both pro-inflammatory cytokines can upregulate MACC1 gene expression in a dose- and time-dependent manner. This effect was more
pronounced for TNF-α. All experiments were performed as three biologically independent experiments. The data are presented as mean ± SEM with the statistical
significance levels: *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001.
pro-inflammatory cytokine IFN-γ on cell migration, HCT116
cells were treated with increasing concentrations of IFN-γ. This
cytokine induced cell migration by 2-fold at concentrations of 1
as well as 10 ng/ml as compared with the unstimulated control
cells (Figure 3B). However, the treatment with 100 ng/ml IFN-
γ did not result in significant changes of cell migration. The
data show that pro-inflammatory cytokines induce cell migration
that is paralleled by an increased MACC1 expression. This was
most efficient at lower concentrations of TNF-α and the effect of
TNF-α was more pronounced than the effect of IFN-γ.
TNF-α Induces MACC1 via c-Jun
We have shown that MACC1 expression is regulated by the
transcription factors AP-1 and SP1 (35). The transcription factor
AP-1 is composed of two subunits with c-Jun being one of
them. Here, the role of TNF-α on c-Jun activity driving MACC1
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FIGURE 3 | MACC1 induced by pro-inflammatory cytokines increases migration. MACC1-dependent cell migration was confirmed by stable MACC1 overexpression
or MACC1 siRNA-mediated MACC1 down-regulation. Cells were treated with either TNF-α (A) of IFN-γ (B) for 24 h before cell migration was measured. Results are
representative of at least four independent experiments. The data are presented as mean ± SEM with the statistical significance levels: **p ≤ 0.01; ***p ≤ 0.001 and
****p ≤ 0.0001.
expression was investigated in CRC cells. The CRC cell line
HCT116 was treated with increasing concentrations of TNF-α
for 24 and 48 h. TNF-α potently stimulates c-Jun expression in a
concentration-dependent manner at both the mRNA and protein
level at 24 h (Figure 4A). The induction of c-Jun expression
declined within 48 h after TNF-α application.
Besides c-Jun, the transcription factor Sp1 has been identified
to bind and regulate the promoter of MACC1 (35). Like c-Jun,
Sp1 activity can be regulated by TNF-α. HCT116 cells were
treated with increasing concentrations of TNF-α for 24 and 48 h
(Figure 4). Sp1 mRNA levels were subsequently determined by
qRT-PCR. The mRNA levels of Sp1 were unchanged following
TNF-α stimulation (Figure 4B). This suggests that TNF-α
stimulation results in an increase of c-Jun transcription. In turn,
elevated c-Jun protein levels led to increased MACC1 expression.
Since TNF-α treatment induced c-Jun, the role of the
pro-inflammatory cytokine IFN-γ on the induction of c-Jun
was also explored. HCT116 cells were treated with increasing
concentrations of IFN-γ, and harvested after 24 or 48 h for
analysis of c-Jun mRNA expression. No induction of c-Jun
mRNA was seen in HCT116 cells (Figure 4C) following IFN-
γ stimulation for 24 or 48 h. Similarly, the role of IFN-γ on
the induction of Sp1 was also explored. Cells were treated with
increasing concentrations of IFN-γ for 24 and 48 h (Figure 4D).
Sp1 mRNA expression levels were subsequently analyzed by
qRT-PCR. Similarly to TNF-α treatment, no induction of Sp1
mRNA expression was detected at any treatment concentration
or time point. This indicates that IFN-γ has no effect on Sp1
expression. In conclusion, we demonstrated that TNF-α induces
the expression of c-Jun, thereby impacting the control of MACC1
expression. Since TNF-α showed a stronger and more sustained
effect on MACC1 gene expression and cell migration, this
cytokine was further analyzed in more detail.
TNF-α Regulates MACC1 Promoter Activity
Through c-Jun/AP-1 Interacting With a
Functional AP-1 Transcription Factor
Binding Site
We previously have cloned and described the MACC1 core
promoter. We reported that MACC1 gene transcription relies
on AP-1 and Sp1 protein activity and their respective promoter
binding sites (35). As TNF-α induces c-Jun expression, a subunit
of AP-1, we tested if this transcription factor has a direct role
in MACC1 gene regulation after TNF-α stimulation. In parallel,
Sp1 was also tested. We mutated the AP-1 and Sp1 transcription
factor binding sites within the MACC1 promoter by site directed
mutagenesis (35). HCT116 cells were transiently transfected with
these AP-1 and Sp1 mutant promoter plasmids together with
a renilla luciferase control plasmid for 24 h. Following TNF-α
treatment for another 24 h, the luciferase activity as read out
for the MACC1 promoter activity was analyzed using the Dual
Luciferase reporter gene assay. Both the mutated AP-1 and Sp1
sites markedly reduced MACC1 promoter activity, accounting
for the crucial role of the two binding sites for MACC1 promoter
function (Figure 5A). TNF-α was able to induce the activity of
the MACC1 promoter but failed to show this increase if the AP-1
or Sp1 binding site was mutated (Figure 5A). Since TNF-α was
able to increase c-Jun but not Sp1 gene expression we tested,
if siRNA mediated knock down of c-Jun impairs MACC1 gene
expression and regulation by TNF-α (Figures 5B,C). Successful
siRNA mediated c-Jun down regulation (Figure 5B) markedly
reduced MACC1 gene expression (Figure 5C). Under these
conditions, TNF-α treatment failed to increase c-Jun expression
and subsequently MACC1 was not induced (Figures 5B,C). In
summary, the AP-1 and Sp1 binding sites are indispensable
elements for the transcriptional activation of the MACC1 gene.
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FIGURE 4 | TNF-α increases c-Jun mRNA and protein expression. HCT116 CRC cells were treated with increasing concentrations of TNF-α (A,B) or IFN-γ (C,D) for
24 (left panels) and 48 h (right panels). Cells without TNF-α treatment served as controls. The mRNA and protein expression levels of c-Jun and Sp1 were measured
by qRT-PCR. Western blot was used to confirm the upregulation at the mRNA level. TNF-α treatment induces c-Jun expression at the mRNA and protein level.
Results are representative of at least three independent experiments. The data are presented as mean ± SEM with the statistical significance levels: ***p ≤ 0.001 and
****p ≤ 0.0001.
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FIGURE 5 | TNF-α induces MACC1 via c-Jun/AP1. (A) HCT116 cells were transiently transfected with the MACC1 promoter reporter plasmids with either mutated
AP-1 or Sp1 transcription factor binding sites along with a renilla luciferase control plasmid for 24 h. Cells were then treated with increasing concentrations of TNF-α.
After 24 h of TNF-α treatment luciferase activity was measured and normalized to renilla luciferase activity. (B,C) HCT116 cells were transfected with the target-specific
predesigned c-Jun siRNA or scrambled control siRNA for 24 h. Cells were then stimulated with increasing concentrations of TNF-α for another 24 h. Cells without
TNF-α treatment served as controls. Cells were analyzed to assess the c-Jun and MACC1 mRNA and protein expression levels using qRT-PCR and Western blotting,
respectively. The data is presented as mean ± SEM with the statistical significance levels: **p ≤ 0.01, ***p ≤ 0.001, and ****p ≤ 0.0001.
In the context of TNF-α stimulation, the induction of MACC1
relies on the functional AP-1 transcription factor binding site.
Signaling Through TNFR1 and NF-κB
Activates c-Jun for MACC1 Induction
TNF-α exerts its effects through binding to two membrane
receptors, TNFR1 or TNFR2 (36–38). These receptors show
different expression patterns: TNFR1 is extensively expressed in
many cell types; but TNFR2 shows a limited expression range
and is selectively found in immune and endothelial cells (38).
Since TNF-α triggers MACC1 expression, we were interested
in identifying the responsible receptor mediating this effect in
cancer cells. To identify the responsible receptor in our model
system, HCT116 cells were pre-incubated with specific blocking
antibodies for either TNFR1 or TNFR2 for 1 h. Afterwards,
the cells were stimulated with 10 ng/ml TNF-α. Following 24 h
of TNF-α treatment, cells were harvested and analyzed for c-
Jun and MACC1 expression both at the mRNA and protein
levels. TNF-α stimulation upregulated both c-Jun and MACC1
expression in the control group. However, the upregulation
of c-Jun (Figure 6A) disappeared at both the mRNA and
protein level upon pretreatment with a TNFR1-specific blocking
antibody. Contrary, TNF-α treatment successfully upregulated
c-Jun expression, despite pretreatment with TNFR2-specific
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FIGURE 6 | TNFRI is the major receptor responsible for TNF-α mediated MACC1 induction. (A,B) One hour prior treatment with 10 ng/ml TNF-α HCT1116 cells were
pre-incubated with specific blocking antibodies targeting TNFR1 or TNFR2 for 24 h. Cells were harvested and analyzed to assess the c-Jun (A) and MACC1 (B)
mRNA and protein expression levels using qRT-PCR and Western blot, respectively. Isotype IgG antibodies not targeting the TNF receptors served as negative
controls. (C–E) HCT116 cells were transfected with p65 siRNA or scrambled control for 24 h. Cells were then treated with increasing concentrations of TNF-α for
another 24 h. Total RNA was extracted, reverse transcribed and the mRNA levels of p65 (C), c-Jun (D), and MACC1 (E) were quantified using qRT-PCR. The data are
presented as mean ± SEM with the statistical significance levels: *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001 and ****p ≤ 0.0001.
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blocking antibodies. This shows, that TNFR2 has only a minor
role in regulating MACC1 expression after TNF-α stimulation.
In accordance with the c-Jun expression pattern, the mRNA
and protein expression levels of MACC1 (Figure 6B) showed
no increase after TNF-α treatment upon pretreatment with
a TNFR1-specific blocking antibody. As for c-Jun, MACC1
expression was still up-regulated upon pretreatment with a
TNFR2-specific blocking antibody.
The pro-inflammatory NF-κB signaling is activated by at least
three pathways (39). One of these pathways is the so-called
“canonical” pathway triggered by TNF-α, which results in the
activation of p65 that regulates the inflammatory responses (40).
HCT116 cells were transfected with siRNA targeting p65 for
24 h. The cells were treated with increasing concentrations of
TNF-α for another 24 h. Unstimulated cells served as controls.
The mRNA expression levels of p65 (Figure 6C) were increased
in a concentration-dependent manner by TNF-α treatment.
Successful knock down of p65 abolished the induction of p65
by TNF-α stimulation. Next, the mRNA expression levels of
c-Jun and MACC1 were examined. Again, both proteins were
up-regulated by TNF-α treatment in a dose-dependent manner.
Knock down of p65 abated basal mRNA expression levels of c-
Jun (Figure 6D) and MACC1 (Figure 6E). The cells with p65
knock down showed only a marginal dose-dependent response
to TNF-α treatment.
In conclusion, TNF-α executed c-Jun and MACC1 induction
through TNFR1, but not TNFR2. Blocking TNFR1, but not
TNFR2, inhibited both c-Jun and MACC1 induction by TNF-
α at the mRNA and protein level. Additionally, c-Jun and
MACC1mRNA expression were inhibited by knock down of p65,
indicating that the canonical NF-κB pathway is directly involved
in the induction of c-Jun that regulates the MACC1 gene.
Adalimumab Can Reverse the TNF-α
Induced MACC1 Expression
Adalimumab is a clinically approved TNF-α neutralizing
monoclonal antibody applied widely in the treatment of
chronic inflammatory diseases including Crohn’s disease and
ulcerative colitis. We therefore tested, if adalimumab can
inhibit the TNF-α induced MACC1 induction. HCT116 cells
were co-administered with 10 ng/ml TNF-α and increasing
concentrations of adalimumab before MACC1 mRNA and
protein expression was determined via qRT-PCR and Western
blot, respectively. Compared to control cells, adalimumab
treatment resulted in a significant decrease in MACC1 gene
expression at all adalimumab concentrations tested (Figure 7). In
addition we tested if adalimumab can revert the TNF-α effect in
the wound healing (scratch) assay. Cellular motility is increased
if cells are stimulated with TNF-α (Supplementary Figure 2A).
If the cells are treated with adalimumab in parallel this effect is
reverted to control levels (Supplementary Figure 2B).
These data confirm our previous findings that TNF-α
increases MACC1 expression. More importantly, it demonstrates
that adalimumab effectively inhibits TNF-α action and reduces
its effect on MACC1 expression.
FIGURE 7 | Effect of TNF-α and the TNF-α neutralizing antibody adalimumab
treatment on MACC1 mRNA and protein expression. HCT116 cells were
treated with 10 ng/ml TNF-α and increasing concentrations of adalimumab (1,
10, 100µg/ml) for 24 h before RNA isolation and qRT-PCR. TNF-α increased
MACC1 gene expression at the mRNA and protein level that was abolished by
blocking TNF-α with adalimumab. The data are presented as mean ± SEM
with the statistical significance levels: ***p ≤ 0.001 and **** p ≤ 0.0001.
DISCUSSION
The close connection of inflammation and cancer is long known
(41), but how inflammatory processes drive cancer development
and progression is not thoroughly described. Here we report,
that MACC1, a prognostic and predictive marker for numerous
solid cancer entities, is increased in inflamed tissues.We analyzed
in detail, how major pro-inflammatory cytokines mediate this
elevated MACC1 gene expression leading to increased cellular
motility. Most importantly, we show that the clinically approved
TNF-α blocking antibody adalimumab can prevent the increase
in MACC1 gene expression, offering a potential treatment option
for patients.
The connection of inflammation and cancer, particularly
CRC, involving pro-inflammatory cytokines was shown by
numerous studies (42–44). Although the link of inflammation
and cancer metastasis is already described, the cell specific
and inflammation induced molecular mechanisms enabling
cancer cells to metastasize are not thoroughly described (45–
47). Expression of the MACC1 gene, particularly in CRC, can
result in tumor invasion and metastasis. It is not known,
why MACC1 expression increases during tumor development.
It was demonstrated that MACC1 expression can be induced
by IL-4 and lipopolysaccharide (LPS) in bone marrow-derived
macrophages, suggesting that MACC1 might be involved in
inflammatory processes (48). Therefore, an examination of
the MACC1 gene regulation, particularly during inflammation,
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can help to clarify the relationship between inflammation,
carcinogenesis and metastasis in CRC.
We have shown that MACC1 expression is increased
in inflamed tissue of ulcerative colitis and Crohn’s disease
patients. It is well accepted that TNF-α and IFN-γ are
major players in the pathogenesis of these chronic diseases
(49). Therefore, we hypothesized that these pro-inflammatory
cytokines regulate MACC1 gene expression in CRC cells. We
demonstrated here, that particularly TNF-α regulates MACC1
at both the transcriptional and translational level in a time-
and dose-dependent manner. Thus, the chronic inflammatory
microenvironment sustained by TNF-α might be an important
condition of CRC progression. Inflammation regulates many
aspects of cancer progression like proliferation, angiogenesis,
invasion, and metastasis (50). For different tumor entities, not
only time but cytokine concentration decides about molecular
outcome (51, 52). We found that TNF-α concentrations affect
levels of MACC1 mRNA and protein expression in a dose-
dependent manner.
IncreasedMACC1 expression leads to cellular motility in vitro
and metastasis in vivo (29). TNF-α was demonstrated as inducer
of cell migration in cancer cells (53). TNF-α can contribute
to migration of CRC cells through the epithelial-mesenchymal
transition (EMT) (54). This process is further promoted by the
combined activity of pro-inflammatory cytokines and MACC1.
We found that low concentrations of TNF-α augment MACC1-
induced cell migration, whereas high doses of TNF-α hinders
cell migration in CRC cells overexpressing MACC1. In this
setting cell death overrules the stimulating effects of TNF-
α (55). Silencing of MACC1 mRNA abrogates the effects of
TNF-α on cell migration and precludes cell responsiveness to
TNF-α treatment. Hence, TNF-α increases cell migration by
acting besides other factors, through the MACC1 gene, thereby
augmenting the migratory potential of MACC1 in CRC.
The transcription factor c-Jun is stimulated by TNF-α through
c-Jun N-terminal kinase (JNK) (56). This classical signaling
pathway is known to be involved in inflammation and cancer
(57, 58).We analyzed c-JunmRNA and protein levels in response
to TNF-α treatment and found that TNF-α induced transcription
and translation of c-Jun in a dose-dependent manner in CRC
cells. Hence, TNF-α can facilitate a variety of pathophysiological
activities directly or indirectly by regulating c-Jun expression.
This pathway is not only relevant for CRC, but for other tumor
entities as well, like hepatocellular carcinoma, pancreatic cancer
or nasopharyngeal carcinoma (59–61).
The c-Jun protein increased by TNF-α is part of the
transcription factor AP-1 that was identified to drive
MACC1 gene expression. The core promoter of MACC1
was identified between the nucleotides −992 to −18 relative to
the transcriptional start site. This region drives transcription of
the MACC1 gene with most of the regulatory features (35). The
minimal essential core promoter region of MACC1 lies within
nucleotides −426 to −18. It encompasses all sequences needed
for MACC1 transcription, including initiation of transcription
and basal activation of the MACC1 gene. The core promoter
region contains functional binding sites for transcription factors,
including AP-1, Sp1, and C/EBPs, which were shown to regulate
MACC1 expression (35).
TNF-α mediates a variety of cell-signaling processes involved
in the immune response and carcinogenesis, primarily via its
interaction with TNFR1 and/or TNFR2 (62, 63). TNFR1 is
a central regulator of signal transduction pathways whereas
TNFR2 is expressed on a very narrow subset of immune cells
(64–66). Based on our previous study on the effects of TNF-α
on c-Jun/MACC1 signaling, we exposed CRC cells to blocking
antibodies for TNFR1 or TNFR2, respectively. Blocking of
TNFR1 did not change the basal MACC1 expression level but
caused a loss of responsiveness of c-Jun and MACC1 mRNA and
protein expression to TNF-α stimulation. In contrast, exposure to
anti-TNFR2 antibodies did not preclude the stimulation of c-Jun
and MACC1 by TNF-α. These results show that TNF-α induces
c-Jun and MACC1 via TNFR1 signaling, but not TNFR2. Thus,
these findings confirm a signaling axis comprising TNFR1 and
c-Jun, leading to MACC1 expression that eventually mediates
tumor progression and metastasis.
TNF-α induces NF-κB to activate signal transductions
processes. NF-κB is a multifunctional transcription factor
with essential roles in a variety of biological activities and
cellular responses. NF-κB subunits form various homo- and
heterodimers. In the canonical pathway, NF-κB is activated by
pro-inflammatory cytokines, such as TNF-α (67).
Consistent with previous studies, we determined that TNF-α
activates c-Jun to regulate the induction of MACC1 in CRC cells.
We explored the effects of NF-κB signaling on c-Jun andMACC1
by knocking down p65. Our results showed that TNF-α increases
the levels of p65 mRNA expression in a dose-dependent manner.
In the context of p65 knockdown, the basal levels of c-Jun and
MACC1 mRNA were lower and the TNF-α responsiveness was
mainly lost. Therefore, the canonical NFκB pathway induces via
p65—a subunit of NF-κB—directly or indirectly the transcription
of c-Jun and controls the induction of MACC1 in CRC cells.
Our findings indicate a notable signaling network involved in
cancer development.
TNF-α activates NF-κB signaling, thereby contributing to
inflammation, cell survival, proliferation, angiogenesis, tumor
promotion, and metastasis (68, 69). The transcription factor
NF-κB links inflammatory signaling and cancer. It is involved
in nearly every stage of cancer development, including
invasion and metastasis. NF-κB promotes tumor metastasis by
regulating epithelial mesenchymal-transition (EMT) in CRC
(70, 71). Furthermore, TNF-α, secreted by pro-inflammatory
macrophages, enhances the metastatic potential of ovarian tumor
cells via activation of the NF-κB signaling pathway (72).
With TNF-α/TNFR1, confidently established as an inducer
of MACC1, we investigated whether a clinically approved
TNF-α blocking antibody would prevent the induction of
MACC1. The human TNF-α blocking monoclonal antibody
adalimumab was used. Adalimumab is used in the treatment
of a number of chronic inflammatory diseases, including
rheumatoid arthritis, colitis ulcerosa or Crohn’s disease.
Adalimumab has been shown to induce apoptosis of human
macrophages while down regulating levels of soluble TNF-α
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as well as other pro-inflammatory cytokines (73–75). Here
we show that adalimumab reduces TNF-α induced MACC1
over-expression. This indicates that a TNF-α specific antibody
could be effective for treatment of MACC1 driven tumors.
Interfering with MACC1 expression via TNF-α could prove
to be a valuable additional therapeutic strategy against
CRC metastasis.
Taken together, our findings support the hypothesis that the
transcription factors c-Jun and NF-κB can be considered as a
potential molecular target in CRC therapy for MACC1 driven
tumors. Control of inflammation offers an effective approach for
repressing or maybe even preventing tumor metastasis.
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Supplementary Figure 1 | Effects of TNF-α on the MACC1 gene expression in
different cell lines. Three different established cells and primary cell cultures were
treated with increasing concentrations of TNF-α (1, 10, 100 ng/ml). Cells without
cytokine treatment served as controls. MACC1 mRNA expression levels were
determined by qRT-PCR. The pro-inflammatory cytokine TNF-α can upregulate
MACC1 gene expression in a dose-dependent manner. The experiments were
performed as three biologically independent experiments. The data are presented
as mean ± SEM with the statistical significance levels: ∗p ≤ 0.05; ∗∗p ≤ 0.01.
Supplementary Figure 2 | TNF-α increases cellular motility in the wound healing
(scratch) assay that is reverted by adalimumab. HCT116 cells were seeded at a
density of 1.1 × 106 cells per ml in 96-well image lock plates. The cells were
allowed to adhere for 6 h forming a confluent monolayer. Wounds (scratches) were
applied using the wound maker tool. Directly after wounding the cells were treated
with increasing amounts of TNF-α (1, 10, and 100 ng/ml) alone or in combination
with 100µg/ml adalimumab. The cells were monitored label-free every second
hour in the IncuCyte live cell imaging system. TNF-α increased wound closure in a
dose-dependent manner over time (A). This phenotype could be reverted
by adalimumab (B).
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